<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20336775</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4547</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>2207</StartPage><EndPage>2216</EndPage><MedlinePgn>2207-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jnr.22389</ELocationID><Abstract><AbstractText>Expanded polyglutamine tracts cause neurodegeneration through a toxic gain-of-function mechanism. Generation of inclusions is a common feature of polyglutamine diseases and other protein misfolding disorders. Inclusion formation is likely to be a defensive response of the cell to the presence of unfolded protein. Recently, the compound B2 has been shown to increase inclusion formation and decrease toxicity of polyglutamine-expanded huntingtin in cultured cells. We explored the effect of B2 on spinal and bulbar muscular atrophy (SBMA). SBMA is caused by expansion of polyglutamine in the androgen receptor (AR) and is characterized by the loss of motor neurons in the brainstem and spinal cord. We found that B2 increases the deposition of mutant AR into nuclear inclusions, without altering the ligand-induced aggregation, expression, or subcellular distribution of the mutant protein. The effect of B2 on inclusions was associated with a decrease in AR transactivation function. We show that B2 reduces mutant AR toxicity in cell and fly models of SBMA, further supporting the idea that accumulation of polyglutamine-expanded protein into inclusions is protective. Our findings suggest B2 as a novel approach to therapy for SBMA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palazzolo</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, NINDS, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nedelsky</LastName><ForeName>Natalia B</ForeName><Initials>NB</Initials></Author><Author ValidYN="Y"><LastName>Askew</LastName><ForeName>Caitlin E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Harmison</LastName><ForeName>George G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Kasantsev</LastName><ForeName>Aleksey G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Pennuto</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS053825</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS053825</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C553048">5-(4-(4-chlorobenzoyl)-1-piperazinyl)-8-nitroquinoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009600">Nitroquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042541" MajorTopicYN="N">Intracellular Space</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045586" MajorTopicYN="N">Intranuclear Inclusion Bodies</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009600" MajorTopicYN="N">Nitroquinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>. The authors declare that no conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20336775</ArticleId><ArticleId IdType="mid">NIHMS522781</ArticleId><ArticleId IdType="pmc">PMC3881232</ArticleId><ArticleId IdType="doi">10.1002/jnr.22389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Yoshida M, Hashizume Y, Sobue G. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005;128(Pt 3):659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659427</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, Waza M, Katsuno M, Tanaka F, Doyu M, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol Appl Neurobiol. 2007;33(2):135&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17359355</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, McLean PJ, Young AB, Housman DE, Kazantsev AG. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A. 2006;103(11):4246&#x2013;4251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449678</ArticleId><ArticleId IdType="pubmed">16537516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BP, Paulson HL, Merry DE, Salazar-Grueso EF, Brinkmann AO, Wilson EM, Fischbeck KH. Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis. 1997;3(4):313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173928</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">10102273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaud AL, Zoghbi HY. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 1999;24(4):879&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">10624951</ArticleId></ArticleIdList></Reference><Reference><Citation>Faus H, Haendler B. Androgen receptor acetylation sites differentially regulate gene control. J Cell Biochem. 2008;104(2):511&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">18022799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck MPaK. Therapeutic prospects for polyglutamine disease. In: Dobson CMKJ, Ramirez-Alvarado M, editors. Protein Misfolding Diseases: Current and Emerging Principles. Hoboken: John Wiley &amp; Sons; in press.</Citation></Reference><Reference><Citation>Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, Powell MJ, Yang T, Gu W, Avantaggiati ML, Pattabiraman N, Pestell TG, Wang F, Quong AA, Wang C, Pestell RG. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26(21):8122&#x2013;8135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636736</ArticleId><ArticleId IdType="pubmed">16923962</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Janne OA, Muratoglu S, Avantaggiati ML, Pestell RG. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003;23(23):8563&#x2013;8575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC262657</ArticleId><ArticleId IdType="pubmed">14612401</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000;275(27):20853&#x2013;20860.</Citation><ArticleIdList><ArticleId IdType="pubmed">10779504</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol. 1999;146(6):1239&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2156127</ArticleId><ArticleId IdType="pubmed">10491388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311(5766):1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 2007;67(9):4514&#x2013;4523.</Citation><ArticleIdList><ArticleId IdType="pubmed">17483368</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtz-Heppelmann CJ, Algeciras A, Badley AD, Paya CV. Transcriptional regulation of the human FasL promoter-enhancer region. J Biol Chem. 1998;273(8):4416&#x2013;4423.</Citation><ArticleIdList><ArticleId IdType="pubmed">9468493</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9(6):768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, Doyu M, Sobue G. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA) Exp Neurol. 2006;200(1):8&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513111</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem. 2007;282(5):3157&#x2013;3164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17121819</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998;44(2):249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002;11(17):1967&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, Zoghbi HY. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature. 2008;452(7188):713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377396</ArticleId><ArticleId IdType="pubmed">18337722</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto H, Sasaki Y. Staurosporine, a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells. Biochem Biophys Res Commun. 1989;158(1):105&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912441</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci. 2007;30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007;317(5837):516&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17588900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW, Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet. 2007;16(13):1593&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M, Sobue G, Taylor JP, Sumner CJ, Fischbeck KH, Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63(3):316&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, Padmanabhan R, Hild M, Berry DL, Garza D, Hubbert CC, Yao TP, Baehrecke EH, Taylor JP. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature. 2007;447(7146):859&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568747</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A. 1994;91(12):5355&#x2013;5358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43993</ArticleId><ArticleId IdType="pubmed">8202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol. 2004;25(1):1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15183036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(Suppl):S10&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Rub U, de Vos RA, Brunt ER, Sebesteny T, Schols L, Auburger G, Bohl J, Ghebremedhin E, Gierga K, Seidel K, den Dunnen W, Heinsen H, Paulson H, Deller T. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol. 2006;16(3):218&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">16911479</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95(1):55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59(5):770&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci U S A. 2005;102(32):11402&#x2013;11407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183566</ArticleId><ArticleId IdType="pubmed">16076956</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, Miura M, Tabata T, Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35(5):855&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986;135(2):397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">3457562</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296(5575):1991&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065827</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, Fischbeck KH. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet. 2003;12(7):749&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651870</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M, Dadgar N, Aphale A, Harrell JM, Kunkel R, Pratt WB, Lieberman AP. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem. 2004;279(9):8389&#x2013;8395.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670946</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas PS, Jr, Fraley GS, Damian V, Woodke LB, Zapata F, Sopher BL, Plymate SR, La Spada AR. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum Mol Genet. 2006;15(14):2225&#x2013;2238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772330</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem. 2002;277(52):50855&#x2013;50859.</Citation><ArticleIdList><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol. 1999;145(3):481&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185077</ArticleId><ArticleId IdType="pubmed">10225950</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, Lieberman AP. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest. 2006;116(10):2663&#x2013;2672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>